Want to see TSE:RAMM full AI Analyst Report?
RAMM Stock Chart & Stats
C$0.01
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.01
C$0.00(0.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.25
Previous CloseN/A
Volume1.00K
Average Volume (3M)118.29K
Market Cap
C$1.19M
Enterprise ValueC$866.77K
Total Cash (Recent Filing)C$119.55K
Total Debt (Recent Filing)C$44.17K
Price to Earnings (P/E)―
Beta-3.31
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding119,389,320
10 Day Avg. Volume262,784
30 Day Avg. Volume118,288
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.53
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces fixed financial obligations and refinancing exposure. This gives Ramm Pharma greater flexibility to restructure operations or fund development than a similarly loss-making company with substantial leverage.
Narrower Net LossesThe reduction in annual losses indicates some progress in controlling the cost base, even though the company remains far from breakeven. Sustained improvement could reduce future funding needs and improve operating resilience.
Improving Cash Burn TrendLower operating cash outflows suggest that cash consumption may be moderating. If maintained alongside operational improvements, this trend could extend the company’s funding runway, although current cash generation remains insufficient for self-funded operations.
Bears Say
Shrinking Revenue BaseMulti-year revenue contraction indicates weakening product demand, distribution reach, or competitive positioning. A shrinking sales base makes it harder to absorb fixed costs, achieve scale, and support investment in pharmaceutical growth opportunities.
Severe UnprofitabilityExtremely thin gross margin and large losses show that current products are not generating adequate economic returns. Persistent unprofitability limits internally funded growth and leaves the business vulnerable to further cost increases or execution setbacks.
Eroded Equity CushionThe substantial decline in equity reflects cumulative losses and materially reduces the company’s capital cushion. Despite low debt, limited equity can constrain strategic investment, weaken resilience, and increase dependence on external financing.
Ramm Pharma News
RAMM FAQ
What was Ramm Pharma’s price range in the past 12 months?
Ramm Pharma lowest stock price was <C$0.01 and its highest was C$0.25 in the past 12 months.
What is Ramm Pharma’s market cap?
Ramm Pharma’s market cap is C$1.19M.
When is Ramm Pharma’s upcoming earnings report date?
Ramm Pharma’s upcoming earnings report date is Sep 24, 2026 which is in 30 days.
How were Ramm Pharma’s earnings last quarter?
Ramm Pharma released its earnings results on Jun 30, 2026. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.002.
Is Ramm Pharma overvalued?
According to Wall Street analysts Ramm Pharma’s price is currently Overvalued.
Does Ramm Pharma pay dividends?
Ramm Pharma does not currently pay dividends.
What is Ramm Pharma’s EPS estimate?
Ramm Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ramm Pharma have?
Ramm Pharma has 119,389,320 shares outstanding.
What happened to Ramm Pharma’s price movement after its last earnings report?
Ramm Pharma reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ramm Pharma?
Currently, no hedge funds are holding shares in TSE:RAMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ramm Pharma
RAMM Pharma Corp., together with its subsidiaries, operates in the pharmaceutical and medical product business in Uruguay and Poland. The company offers cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products; and pharmaceuticals, cosmetics, and nutraceutical products. It also engages in the resale of medical supplies products; and the sale of medical devices and consumables. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.